Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. 2014

Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065.

Levodopa treatment is the major pharmacotherapy for Parkinson's disease. However, almost all patients receiving levodopa eventually develop debilitating involuntary movements (dyskinesia). Although it is known that striatal spiny projection neurons (SPNs) are involved in the genesis of this movement disorder, the molecular basis of dyskinesia is not understood. In this study, we identify distinct cell-type-specific gene-expression changes that occur in subclasses of SPNs upon induction of a parkinsonian lesion followed by chronic levodopa treatment. We identify several hundred genes, the expression of which is correlated with levodopa dose, many of which are under the control of activator protein-1 and ERK signaling. Despite homeostatic adaptations involving several signaling modulators, activator protein-1-dependent gene expression remains highly dysregulated in direct pathway SPNs upon chronic levodopa treatment. We also discuss which molecular pathways are most likely to dampen abnormal dopaminoceptive signaling in spiny projection neurons, hence providing potential targets for antidyskinetic treatments in Parkinson's disease.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
January 2023, Frontiers in neuroscience,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
February 2018, Neuron,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
October 2022, iScience,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
November 2002, Proceedings of the National Academy of Sciences of the United States of America,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
March 2009, Proceedings of the National Academy of Sciences of the United States of America,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
November 2013, Journal of neurophysiology,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
March 2014, Movement disorders : official journal of the Movement Disorder Society,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
July 2008, Journal of neurochemistry,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
June 2018, Cell reports,
Myriam Heiman, and Adrian Heilbut, and Veronica Francardo, and Ruth Kulicke, and Robert J Fenster, and Eric D Kolaczyk, and Jill P Mesirov, and Dalton J Surmeier, and M Angela Cenci, and Paul Greengard
May 2022, Neurobiology of disease,
Copied contents to your clipboard!